COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report

S. Grundy, H. Arai, P. Barter, T. Bersot, D. Betteridge, R. Carmena, A. Cuevas, M. Davidson, J. Genest, Y. Kesäniemi, S. Sadikot, R. Santos, A. Susekov, R. Sy, S. LaleTokgözoglu, G. Watts, D. Zhao,
2021
https://doi.org/10.1016/j.jacl.2013.12.005

An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non - high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins. © 2014 National Lipid Association. All rights reserved.

Цитирование

Похожие публикации

Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: An international expert position paper
S. Omboni, R. McManus, H. Bosworth,
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
G. Gerotziafas, M. Catalano, M. Colgan,
Recovery of endoscopy services in the era of COVID-19: Recommendations from an international Delphi consensus
P. Bhandari, S. Subramaniam, M. Bourke,

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • S. Grundy
    Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, TX, United States
  • H. Arai
    Department of Human Health Sciences, Kyoto University, Graduate School of Medicine, Kyoto, Japan
  • P. Barter
    International Atherosclerosis Society, Japan
  • T. Bersot
    Department of Medicine, J. David Gladstone Institutes, University of California San Francisco, San Francisco, CA, United States
  • D. Betteridge
    University College Hospital London and Emeritus, Department of Endocrinology and Metabolism, University College London, London, United Kingdom
  • R. Carmena
    Department of Internal Medicine and Endocrinology, University of Valencia, Spain
  • A. Cuevas
    Department of Nutrition, Clínica Las Condes, Santiago, Chile
  • M. Davidson
    Lipid Clinic, University of Chicago, Pritzker School of Medicine, Chicago, IL, United States
  • J. Genest
    Center for Innovative Medicine, McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
  • Y. Kesäniemi
    Department of Medicine, University of Oulu and Clinical Research Center, Oulu University Hospital, Oulu, Finland
  • S. Sadikot
    Diabetes India, Mumbai, India
  • R. Santos
    Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, University of Sao Paulo, Brazil
  • A. Susekov
    Laboratory of Clinical Lipidology, Department of Atherosclerosis, Cardiology Research Complex, Moscow, Russian Federation
  • R. Sy
    Department of Medicine, University of the Philippines, College of Medicine, Manila, Philippines
  • S. LaleTokgözoglu
    Department of Cardiology, Hacettepe University, Ankara, Turkey
  • G. Watts
    Cardiometabolic Clinic, Royal Perth Hospital, University of Western Australia, Australia
  • D. Zhao
    Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing Anzhen Hospital, Beijing, China
Название журнала
  • Journal of Clinical Lipidology
Том
  • 8
Выпуск
  • 1
Страницы
  • 29-60
Ключевые слова
  • Cholesterol; Dyslipidemia; Lifestyle therapies; Lifetime risk; Metabolic syndrome; Statins; Anticholesteremic Agents; Atherosclerosis; Dyslipidemias; Health Planning Guidelines; Humans; Internationality; Life Style; Risk Factors; Societies, Medical
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY-NC-ND
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON